• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

    11/7/24 7:30:00 AM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CING alert in real time by email

    KANSAS CITY, Kan., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the three months ended September 30, 2024, and provided a clinical and business update.

    "The capital raised this quarter has allowed us to focus on advancing the remaining activities required for NDA submission of our lead ADHD asset, CTx-1301, targeted for mid 2025," said Cingulate Chairman and CEO Shane J. Schaffer. "The granting of European patents for CTx-1301 in up to 30 territories, including the United Kingdom, helps Cingulate expand its reach beyond the United States and makes a positive impact on the growing ADHD markets abroad. Overall, Cingulate finds itself in a stronger position financially and looks forward to filing its first NDA next year."

    Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301

    In September, Cingulate commenced its final FDA-required study, which is a food effect study, for CTx-1301. A data readout from the study is expected by the end of 2024.

    European Patent Granted for Lead Asset CTx-1301 for the Treatment of ADHD

    Cingulate was issued a European patent for its lead asset CTx-1301 for the treatment of ADHD during the third quarter of 2024. This patent will include up to 30 European territories, including the United Kingdom. In addition to the European patent, Cingulate has patents in Australia, Canada and Israel, as well as pending patents in Hong Kong, the Republic of Korea, and the United States.

    Nasdaq Listing Update

    On September 9, 2024, the Nasdaq Hearings Panel notified Cingulate that it had regained compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2).

    Over $12 Million of Capital Raised in the Third Quarter

    Cingulate raised approximately $12.5 million of capital in the third quarter of 2024. The capital raised provides the Company the cash runway to fund the clinical, manufacturing, and regulatory activities, as well as operating activities, into the third quarter of 2025, based on planned expenditures. Cingulate is targeting mid-2025 for the NDA submission of CTx-1301 (dexmethylphenidate) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

    Third Quarter Results

    Cash Position: As of September 30, 2024, Cingulate had approximately $10 million in cash and cash equivalents, a significant increase from December 31, 2023, providing the Company with an extended cash runway into the third quarter of 2025, as noted above.

    Working Capital: As of September 30, 2024, Cingulate had approximately $9.8 million in working capital, an increase of $19.5 million from December 31, 2023. This increase in working capital is reflective of a significant strengthening of the Company's balance sheet resulting from capital raised in 2024.

    Liabilities: As of September 30, 2024, total liabilities were $1.5 million, a decrease from December 31, 2023 of $8.8 million, including the conversion of the related party note payable in the amount of $3.3 million which occurred in the first quarter of 2024.

    Stockholders' Equity: As of September 30, 2024, total stockholders' equity was $12.0 million, an increase of $18.9 million from the end of 2023.

    R&D Expenses: R&D expenses were $1.4 million for the three months ended September 30, 2024, a decrease of $2.5 million from the three months ended September 30, 2023. This change was primarily the result of decreased clinical activity in the three months ended September 30, 2024 as compared to the same period in 2023. During the third quarter of 2023, we incurred significant costs relating to two Phase 3 studies for CTx-1301, the fixed dose pediatric and adolescent safety and efficacy study and the pediatric dose optimization and duration study. Enrollment in these two studies was completed in early 2024 and we are progressing with the remaining close-out and analytical activities required for an NDA submission. Manufacturing costs also decreased as the activity in 2023 was more significant for the manufacture of clinical supply for the Phase 3 studies. In 2024, manufacturing activity included the completion of registration batches of CTx-1301.

    G&A Expenses: Total G&A expenses were $1.9 million for the three months ended September 30, 2024, which was relatively consistent to the three months ended September 30, 2023.

    Net Loss: Net loss was $3.2 million for the three months ended September 30, 2024, compared to $6.0 million for the same period in 2023. The decrease in the net loss primarily related to a decrease in R&D and G&A expenses described above.

          
    Cingulate Inc. 
    Consolidated Balance Sheet Data 
      
      September 30, December 31, 
       2024   2023  
    Cash and cash equivalents $10,040,149  $52,416  
    Total assets $13,580,104  $3,491,436  
    Working Capital $9,801,070  $(9,647,172) 
    Total liabilities $1,542,541  $10,360,865  
    Accumulated deficit $(102,357,201) $(92,943,443) 
    Total stockholders' equity $12,037,563  $(6,869,429) 
              



      
    Cingulate Inc. 
    Consolidated Statements of Operations  
            
      Three Months Ended September 30, Six Months Ended September 30, 
       2024   2023   2024   2023  
    Operating expenses:         
    Research and development $1,428,504  $3,923,852  $5,116,582  $10,508,395  
    General and administrative  1,853,583   1,825,822   4,319,902   5,453,643  
     Operating loss  (3,282,087)  (5,749,674)  (9,436,484)  (15,962,038) 
              
    Interest and other income (expense), net  50,483   (229,380)  22,726   (638,212) 
    Loss before income taxes  (3,231,604)  (5,979,054)  (9,413,758)  (16,600,250) 
    Income tax benefit (expense)  -   -   -   -  
    Net loss  (3,231,604)  (5,979,054)  (9,413,758)  (16,600,250) 
              

    About Cingulate®

    Cingulate Inc. is a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), Cingulate is identifying and evaluating additional therapeutic areas where its PTR technology may be employed to develop future product candidates, such as anxiety disorders.

    Cingulate is headquartered in Kansas City, KS. For more information visit Cingulate.com.

    Forward-Looking Statements 

    This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include all statements, other than statements of historical fact, regarding our current views and assumptions with respect to future events regarding our business, including statements with respect to our plans, assumptions, expectations, beliefs and objectives with respect to product development, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth opportunities and other statements that are predictive in nature. These statements are generally identified by the use of such words as "may," "could," "should," "would," "believe," "anticipate," "forecast," "estimate," "expect," "intend," "plan," "continue," "outlook," "will," "potential" and similar statements of a future or forward-looking nature. Readers are cautioned that any forward-looking information provided by us or on our behalf is not a guarantee of future performance. Actual results may differ materially from those contained in these forward-looking statements as a result of various factors disclosed in our filings with the Securities and Exchange Commission (SEC), including the "Risk Factors" section of our Annual Report on Form 10-K filed with the SEC on April 1, 2024 and our other filings with the SEC. All forward-looking statements speak only as of the date on which they are made, and we undertake no duty to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.

    Investor & Public Relations:

    Thomas Dalton

    Vice President, Investor & Public Relations, Cingulate

    [email protected]

    (913) 942-2301

    Matt Kreps

    Darrow Associates

    [email protected]

    (214) 597-8200



    Primary Logo

    Get the next $CING alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CING

    DatePrice TargetRatingAnalyst
    1/10/2025$12.00Buy
    ROTH MKM
    12/22/2023Buy → Hold
    Laidlaw
    1/20/2022$8.50Buy
    Laidlaw & Co.
    1/11/2022$9.00Buy
    Aegis Capital
    More analyst ratings

    $CING
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by EVP and COO Myers Laurie

      4 - Cingulate Inc. (0001862150) (Issuer)

      2/20/25 6:00:04 PM ET
      $CING
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by SVP and CFO Callahan Jennifer L.

      4 - Cingulate Inc. (0001862150) (Issuer)

      2/20/25 6:00:05 PM ET
      $CING
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Schaffer Shane J.

      4 - Cingulate Inc. (0001862150) (Issuer)

      2/20/25 6:00:02 PM ET
      $CING
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CING
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

      Pre-NDA Meeting for CTx-1301(dexmethylphenidate) Held April 2, 2025; New Drug Application Submission Targeted for Mid-2025 Non-Dilutive Funding to Accelerate Development of CTx-2103 (buspirone) KANSAS CITY, Kan., May 08, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quarter ended March 31, 2025, and provided a clinical and business update. Highlights include the completion of the Pre-NDA meeting for CTx-1301 and grant received to accelerate

      5/8/25 4:30:00 PM ET
      $CING
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD

      Primary Endpoints Demonstrate CTx-1301 Can be Taken With or Without Food CTx-1301 is Designed as a True, Entire Active-Day Treatment for ADHD KANSAS CITY, Kan., April 29, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced positive top-line results from the CTx-1301-013 study, an FDA required study, assessing the effect of food on absorption of the highest dose (50mg) of its lead candidate CTx-1301. CTx-1301 is a novel, investigational, trimodal, extended-release tablet formul

      4/29/25 8:00:00 AM ET
      $CING
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cingulate Receives $3 Million Grant from Private Foundation to Accelerate Development of Anxiety Asset CTx-2103 (buspirone)

      CTx-2103 has the Potential to be the First, Once-Daily Formulation of Buspirone, one of the Most Widely Prescribed Agents in the $5.5 Billion U.S. Anxiety Market, and the $11.6 Billion Anxiety Market Worldwide Non-Dilutive Funding Expands Pipeline and Further Validates Cingulate's Proprietary Precision Timed Release™ Drug Delivery Technology CTx-2103 has the Potential to Reduce Use of Benzodiazepine's and Associated Withdrawal and Dependency Issues KANSAS CITY, Kan., April 09, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advanc

      4/9/25 8:00:00 AM ET
      $CING
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CING
    Leadership Updates

    Live Leadership Updates

    See more
    • Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors

      KANSAS CITY, Kan., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, announced today that it has appointed three new directors to its board: Jay Roberts, Bryan Lawrence, and Jeff Ervin. The appointment of the new directors follows the completion of the Company's recent follow-on offering of $7.5 million in February 2024, sales under the Company's at-the-market offering (ATM) facility in January 2024 of $3.2 million, as well as the conversion of $3.3 million of outstanding debt i

      2/13/24 6:45:00 AM ET
      $BACK
      $CING
      Medical Specialities
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $CING
    Financials

    Live finance-specific insights

    See more
    • Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets

      Pre-NDA Meeting for CTx-1301(dexmethylphenidate) Held April 2, 2025; New Drug Application Submission Targeted for Mid-2025 Non-Dilutive Funding to Accelerate Development of CTx-2103 (buspirone) KANSAS CITY, Kan., May 08, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quarter ended March 31, 2025, and provided a clinical and business update. Highlights include the completion of the Pre-NDA meeting for CTx-1301 and grant received to accelerate

      5/8/25 4:30:00 PM ET
      $CING
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market

      KANSAS CITY, Kan., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the three months ended September 30, 2024, and provided a clinical and business update. "The capital raised this quarter has allowed us to focus on advancing the remaining activities required for NDA submission of our lead ADHD asset, CTx-1301, targeted for mid 2025," said Cingulate Chairman and CEO Shane J. Schaffer. "The granting of European patents for CTx-1301 in up to

      11/7/24 7:30:00 AM ET
      $CING
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cingulate Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update

      CTx-1301 Phase 3 Adult Dose-Optimization Study Ongoing; Results Expected 3Q 2023 Positive Top-Line Data from CTx-1301 Fed/Fast Study Announced, Full Results Submitted for Presentation at Forthcoming Medical Meeting CTx-1301 Pivotal Phase 3 Trial in Pediatric/Adolescent Patients Planned to Begin Mid-2023 KANSAS CITY, Kan., March 10, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the three and 12 months ended December 31, 2022, and provided a clin

      3/10/23 4:05:00 PM ET
      $CING
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CING
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Cingulate with a new price target

      ROTH MKM initiated coverage of Cingulate with a rating of Buy and set a new price target of $12.00

      1/10/25 7:39:52 AM ET
      $CING
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cingulate downgraded by Laidlaw

      Laidlaw downgraded Cingulate from Buy to Hold

      12/22/23 7:22:08 AM ET
      $CING
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Laidlaw & Co. initiated coverage on Cingulate with a new price target

      Laidlaw & Co. initiated coverage of Cingulate with a rating of Buy and set a new price target of $8.50

      1/20/22 9:15:46 AM ET
      $CING
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CING
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Cingulate Inc.

      SC 13G/A - Cingulate Inc. (0001862150) (Subject)

      11/14/24 7:21:05 PM ET
      $CING
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Cingulate Inc.

      SC 13D/A - Cingulate Inc. (0001862150) (Subject)

      8/30/24 6:00:22 PM ET
      $CING
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Cingulate Inc.

      SC 13D/A - Cingulate Inc. (0001862150) (Subject)

      8/20/24 7:00:06 PM ET
      $CING
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CING
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CING
    SEC Filings

    See more
    • Callahan Jennifer L. bought $1,490 worth of shares (55 units at $27.10), increasing direct ownership by 2% to 2,333 units (SEC Form 4)

      4 - Cingulate Inc. (0001862150) (Issuer)

      3/22/24 6:00:15 PM ET
      $CING
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Callahan Jennifer L. bought $3,348 worth of shares (5,000 units at $0.67), increasing direct ownership by 12% to 45,508 units

      4 - Cingulate Inc. (0001862150) (Issuer)

      9/18/23 6:00:26 PM ET
      $CING
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Cingulate Inc.

      10-Q - Cingulate Inc. (0001862150) (Filer)

      5/8/25 4:40:42 PM ET
      $CING
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cingulate Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Cingulate Inc. (0001862150) (Filer)

      5/8/25 4:35:12 PM ET
      $CING
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Cingulate Inc.

      DEFA14A - Cingulate Inc. (0001862150) (Filer)

      4/28/25 5:00:28 PM ET
      $CING
      Biotechnology: Pharmaceutical Preparations
      Health Care